Toshio Shimizu

15PUBLICATIONS
120CO-AUTHORS
Molecular targetsLiquid biopsiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 18, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.

|Apr 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective.

Merel J J Lucassen, Pedro Bergmann, Olga Husson

|Aug 14, 2024
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.

Takafumi Koyama, Kan Yonemori, Toshio Shimizu

|Apr 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Aditya Bardia, Ian E Krop, Takahiro Kogawa

|Jul 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida, Toshio Shimizu, Makoto Nishino

|Jun 27, 2023
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.

Takafumi Koyama, Toshio Shimizu, Yuki Kojima

Pageof 3

Frequent Collaborators

8 joint publications

Noboru Yamamoto

7 joint publications

Kan Yonemori

6 joint publications

Takafumi Koyama

3 joint publications

Tomoko Yanai